Arcutis Biotherapeutics, Inc. granted an aggregate of 61,000 restricted stock units (RSUs) to 9 newly hired employees as a material inducement to employment. The awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 1, 2026. This action was taken in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest over four years, with 25% vesting on each annual anniversary of the vesting commencement date. Vesting is subject to each employee’s continued employment with Arcutis through the applicable vesting date. The company disclosed this information to comply with Nasdaq Listing Rule 5635(c)(4).

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company focused on developing innovations for chronic inflammatory skin diseases. The company has developed a portfolio of targeted topicals approved to treat three major inflammatory skin diseases.

Grant Details

Arcutis Biotherapeutics, Inc. has launched a new virtual health platform designed to expand access pathways to its ZORYVE portfolio for chronic inflammatory skin diseases. The platform connects individuals with independent, board-certified dermatologists through a streamlined digital experience for evaluation and to discuss potential treatment options. This initiative aims to address barriers such as long wait times and geographic limitations for the more than 45 million people in the U.S. living with eczema, seborrheic dermatitis, and plaque psoriasis.

The virtual health platform provides an additional pathway to care for individuals who have yet to see a dermatologist or who struggle with obtaining timely dermatology care. It is designed to complement traditional in-office dermatology specialist care by offering a convenient alternative. After completing a brief clinical intake, individuals are connected with independent dermatologists who evaluate, diagnose, and determine appropriate treatment based on their clinical judgment.

Arcutis does not influence clinical decision-making, diagnoses, or prescribing decisions made through the platform. If prescribed, ZORYVE prescriptions are coordinated through a national pharmacy hub designed to support a seamless experience, including insurance support and home delivery. Alternatively, prescriptions can be sent directly to an individual’s preferred pharmacy.

ZORYVE Portfolio Indications

ZORYVE is a topical formulation of roflumilast, a targeted topical phosphodiesterase type 4 (PDE4) inhibitor. The portfolio includes several approved indications across different age groups and conditions:

Strategic Commitment

The launch of the virtual health platform reflects Arcutis’ broader commitment to improving access to care and treatment for individuals living with chronic inflammatory skin diseases. Todd Edwards, chief commercial officer of Arcutis, stated that the platform is designed to help reduce barriers to specialist treatment and support individuals who may otherwise forego or face delays in seeing a dermatologist. The company continues to engage healthcare providers across dermatology, primary care, and pediatric settings to support patient care.